Capillary electrophoresis and capillary electrophoresis-ion trap multiple-stage mass spectrometry for the differentiation and identification of oxycodone and its major metabolites in human urine

被引:30
作者
Wey, AB [1 ]
Thormann, W [1 ]
机构
[1] Univ Bern, Dept Clin Pharmacol, CH-3010 Bern, Switzerland
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 770卷 / 1-2期
关键词
oxycodone;
D O I
10.1016/S1570-0232(01)00568-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Oxycodone (OCOD) and its metabolites, including oxymorphone (OMOR), noroxycodone (NOCOD) and noroxymorphone (NOMOR), are opioids that carry an OH group at position 14. Using capillary electrophoresis (CE) with a binary phosphate buffer containing 60% ethylene glycol (pH 7.9), the migration order of OCOD and OMOR with respect to their N-demethylated analogs was found to be reversed compared to that observed for codeine, dihydrocodeine, morphine and dihydromorphine, compounds that do not have an OH group at position 14. OCOD and structurally related compounds can also be distinguished from these opioids by their absorbance spectra at low wavelengths and via a characteristic neutral HZO loss at the MS2 level. Using the binary phosphate buffer, CE with UV detection is shown to be capable of monitoring OCOD, NOCOD, OMOR (after hydrolysis only) and NOMOR (after hydrolysis and in patient urine only) in alkaline liquid-liquid extracts of urines that were collected after ingestion of 10 mg OCOD hydrochloride and in a patient urine collected at steady state (80 mg OCOD hydrochloride daily). Using an aqueous pH 9 ammonium acetate buffer, these results were confirmed by CE-MS3. Based on CE-MS, MS2 and MS' data, the absorbance spectra measured across the CE peaks and the relative position within the electropherogram, two peaks monitored in the UV absorbance electropherograms could be assigned to the two keto-reduced metabolites 6oxycodol (6OCOL) and nor6oxycodol, for which no standards were available. Comparison of data obtained with urines pretreated with two different enzyme products (beta-glucuronidase and beta-glucuronidase/arylsulfatase) suggest that OCOD, NOCOD and 6OCOL are mainly glucuronidated, whereas OMOR mainly forms other conjugates. Furthermore, in a first attempt to directly measure conjugates of the compounds of interest, solid-phase extracts were analyzed by CE-MS4, which revealed the presence of the acyl glucuronides of 60COL and OMOR and an unidentified OMOR conjugate. The quantitation of free OCOD and NOCOD by CE-MS using deuterated internal standards is also discussed briefly. (C) 2002 Elsevier Science B V. All rights reserved.
引用
收藏
页码:191 / 205
页数:15
相关论文
共 29 条
[1]  
Hagen NA, 1997, CANCER-AM CANCER SOC, V79, P1428
[2]   Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone [J].
Heiskanen, T ;
Olkkola, KT ;
Kalso, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) :603-611
[3]  
Heiskanen TE, 2000, ACTA ONCOL, V39, P941
[4]   EXPLORATION OF THE METABOLISM OF DIHYDROCODEINE VIA DETERMINATION OF ITS METABOLITES IN HUMAN URINE USING MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY [J].
HUFSCHMID, E ;
THEURILLAT, R ;
MARTIN, U ;
THORMANN, W .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01) :159-170
[5]   Characterization of the genetic polymorphism of dihydrocodeine O-demethylation in man via analysis of urinary dihydrocodeine and dihydromorphine by micellar electrokinetic capillary chromatography [J].
Hufschmid, E ;
Theurillat, R ;
WilderSmith, CH ;
Thormann, W .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 678 (01) :43-51
[6]  
ISHIDA T, 1982, J PHARMACOBIO-DYNAM, V5, P521
[7]  
ISHIDA T, 1979, DRUG METAB DISPOS, V7, P162
[8]  
ISHIDA T, 1982, J PHARMACOBIO-DYNAM, V5, P134
[9]   Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone [J].
Kaiko, RF ;
Benziger, DP ;
Fitzmartin, RD ;
Burke, BE ;
Reder, RF ;
Goldenheim, PD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :52-61
[10]   MORPHINE AND OXYCODONE HYDROCHLORIDE IN THE MANAGEMENT OF CANCER PAIN [J].
KALSO, E ;
VAINIO, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) :639-646